Short Communication - (2025) Volume 17, Issue 3
Received: 01-Jun-2025, Manuscript No. jbabm-26-182340;
Editor assigned: 03-Jun-2025, Pre QC No. P-182340;
Reviewed: 17-Jun-2025, QC No. Q-182340;
Revised: 22-Jun-2025, Manuscript No. R-182340;
Published:
29-Jun-2025
, DOI: 10.37421/1948-593X.2025.17.499
Citation: Park, Min-Joon. ”Electrochemical Biosensors: Advancing Diagnostics and Personalized Medicine.” J Bioanal Biomed 17 (2025):499.
Copyright: © 2025 Park M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Electrochemical bioanalysis represents a powerful and versatile platform for the sensitive and specific detection of biomolecules critical for a wide range of biomedical applications. This field has witnessed substantial progress, particularly in areas such as point-of-care diagnostics, the monitoring of therapeutic drug levels, and the identification of disease biomarkers. The inherent advantages associated with electrochemical methods, including their low cost, potential for miniaturization, and capability for label-free detection, are propelling their integration into the next generation of biomedical tools. Innovations in nanomaterials and advanced surface modification techniques are further enhancing the performance of these sensors, allowing for the detection of analytes at extremely low concentrations, a capability that is paramount for early disease diagnosis and the advancement of personalized medicine. The development of wearable electrochemical sensors has fundamentally transformed the landscape of continuous health monitoring. These sophisticated devices, frequently integrated into flexible substrates, facilitate real-time analysis of key biomarkers found in biofluids such as sweat, interstitial fluid, and blood. This approach offers a non-invasive or minimally invasive means to track physiological parameters and monitor disease progression. Key advancements in this domain encompass the utilization of advanced electrode materials, the implementation of multiplexing capabilities for the simultaneous detection of multiple analytes, and the integration of robust wireless data transmission for remote patient management. This trend is proving particularly impactful in the management of chronic diseases and the optimization of athletic performance. Electrochemical immunoassay platforms have demonstrated significant promise for the accurate detection of disease-specific proteins and antibodies. By leveraging the exceptional specificity of antibody-antigen interactions, these sensors can identify biomarkers with remarkable precision. Recent research efforts have concentrated on enhancing sensitivity and reducing detection limits through strategic approaches such as signal amplification, often employing nanomaterials or enzyme labels. The synergistic integration of microfluidics with electrochemical immunoassay systems further facilitates rapid sample processing and assay miniaturization, thereby paving the way for the development of point-of-care diagnostic devices for a spectrum of conditions, including infectious diseases and various forms of cancer. The application of electrochemical techniques in therapeutic drug monitoring (TDM) is steadily gaining momentum, driven by the increasing need for personalized dosing strategies for a diverse array of medications. Electrochemical sensors are capable of providing rapid and frequent measurements of drug concentrations within biological fluids, enabling clinicians to fine-tune treatment regimens and effectively minimize the occurrence of adverse effects. Current research is actively focused on the development of sensors designed to detect a broader range of drugs, including antibiotics, immunosuppressants, and anticoagulants, with enhanced selectivity and reduced interference from endogenous substances. The prospect of implantable or wearable electrochemical sensors for continuous TDM holds considerable potential for significantly improving patient outcomes. Electrochemical DNA biosensors are instrumental in the field of genetic diagnostics and the detection of nucleic acid-based biomarkers associated with diseases such as cancer and various infectious agents. These sensors harness the specific binding affinity of DNA probes to their target sequences, generating electrochemical signals through diverse transduction mechanisms, including the use of redox indicators or enzymatic reactions. Recent advancements have primarily focused on augmenting sensitivity, specificity, and the capacity for multiplexed target detection, frequently employing nanomaterials and innovative electrode designs to achieve lower limits of detection. This technological advancement is crucial for enabling rapid genetic screening and advancing the goals of personalized medicine. Electrochemical methods are being increasingly utilized for the detection of circulating tumor cells (CTCs) and extracellular vesicles (EVs). These entities are recognized as valuable biomarkers for cancer diagnosis, prognosis, and the monitoring of treatment response. The biosensors employed in this area typically employ various capture strategies, such as specific antibodies or aptamers, to effectively isolate and detect these rare cells or vesicles from complex biological samples. The integration of microfluidic systems with electrochemical detection platforms facilitates efficient enrichment and subsequent analysis, thereby enabling earlier cancer detection and the development of more personalized therapeutic strategies. Ongoing advancements in signal amplification and multiplexing technologies are further enhancing the sensitivity and expanding the analytical scope of these platforms. The incorporation of nanomaterials, including nanoparticles, nanowires, and graphene-based structures, has led to a significant enhancement in the performance of electrochemical biosensors. These advanced materials offer considerable advantages, such as a high surface area-to-volume ratio, enhanced electrical conductivity, and tunable surface chemistry, all of which contribute to improvements in sensitivity, selectivity, and overall sensor stability. In the biomedical arena, electrodes modified with nanomaterials are indispensable for the detection of low-abundance biomarkers, the acceleration of reaction kinetics, and the facilitation of multiplexed detection. Their integration is crucial for the development of ultrasensitive and miniaturized diagnostic devices capable of addressing a wide array of medical conditions. Electrochemical biosensors play a pivotal role in point-of-care testing (POCT) by facilitating rapid, on-site detection of a variety of health indicators. The key advantages offered by electrochemical POCT devices include their portability, user-friendliness, low cost, and their ability to deliver quantitative results in a timely manner. Recent innovations in microfluidics, materials science, and signal processing technologies have culminated in the development of sophisticated POCT devices suitable for diagnosing infectious diseases, monitoring glucose levels, and detecting cardiac biomarkers. This enhanced accessibility is fundamentally transforming healthcare delivery, particularly in remote or resource-limited settings. The development of electrochemical aptasensors has emerged as a highly promising tool for a broad spectrum of biomedical analyses, owing to the unique attributes of aptamers, such as their inherent high specificity, excellent stability, and straightforward synthesis. These aptasensors provide mechanisms for label-free or labeled detection of an extensive array of biomolecules, including proteins, nucleic acids, and small molecules. Advances in aptamer selection and immobilization techniques, when coupled with efficient electrochemical signal transduction, are enabling the creation of sensors with exceptional sensitivity and selectivity for applications in disease diagnosis, drug discovery, and molecular imaging. Electrochemical impedimetric biosensors represent a valuable label-free detection methodology that operates by measuring variations in electrical impedance at the electrode-analyte interface. This approach is particularly advantageous for the detection of biomolecules that are inherently difficult to label or when the intrinsic electrochemical properties of the analyte are not conducive to direct measurement. Recent progress in this area involves the strategic use of advanced electrode materials and sophisticated electrochemical models to enhance both sensitivity and specificity. These advancements are enabling applications such as the detection of pathogens, the monitoring of cellular responses, and the quantification of protein-protein interactions within complex biological systems.
Electrochemical bioanalysis provides a sensitive and specific platform for detecting biomolecules relevant to biomedical applications. This field has seen rapid advancements, particularly in point-of-care diagnostics, therapeutic drug monitoring, and disease biomarker identification. The inherent advantages of electrochemical methods, such as low cost, miniaturization potential, and label-free detection capabilities, are driving their integration into next-generation biomedical tools. Innovations in nanomaterials and surface modification techniques are further enhancing sensor performance, enabling the detection of analytes at very low concentrations, which is crucial for early disease diagnosis and personalized medicine [1].
The development of wearable electrochemical sensors has revolutionized continuous health monitoring. These devices, often integrated into flexible substrates, allow for real-time analysis of biomarkers in sweat, interstitial fluid, and blood, providing a non-invasive or minimally invasive approach to track physiological parameters and disease progression. Key advancements include the use of advanced electrode materials, multiplexing capabilities for detecting multiple analytes simultaneously, and robust wireless data transmission for remote patient management. This trend is particularly impactful for managing chronic diseases and optimizing athletic performance [2].
Electrochemical immunoassay platforms have demonstrated significant promise for the detection of disease-specific proteins and antibodies. By utilizing the high specificity of antibody-antigen interactions, these sensors can detect biomarkers with remarkable accuracy. Recent progress has focused on improving the sensitivity and reducing the detection limits through strategies like signal amplification using nanomaterials or enzyme labels. The integration of microfluidics with electrochemical immunoassay systems further enables rapid sample processing and assay miniaturization, paving the way for point-of-care diagnostic devices for infectious diseases and cancer [3].
The application of electrochemical techniques in therapeutic drug monitoring (TDM) is gaining traction due to the need for personalized dosing of various medications. Electrochemical sensors can provide rapid and frequent measurements of drug concentrations in biological fluids, allowing clinicians to optimize treatment regimens and minimize adverse effects. Research is focused on developing sensors for a wider range of drugs, including antibiotics, immunosuppressants, and anticoagulants, with enhanced selectivity and reduced interference from endogenous substances. The development of implantable or wearable electrochemical sensors for continuous TDM holds significant potential for improving patient outcomes [4].
Electrochemical DNA biosensors are instrumental in genetic diagnostics and the detection of nucleic acid-based biomarkers for diseases like cancer and infectious agents. These sensors leverage the specific binding of DNA probes to target sequences, with electrochemical signals generated through various transduction mechanisms, including redox indicators or enzymatic reactions. Recent advancements have focused on increasing sensitivity, specificity, and the ability to detect multiplexed targets, employing nanomaterials and innovative electrode designs to achieve lower limits of detection. This technology is crucial for rapid genetic screening and personalized medicine [5].
Electrochemical methods are increasingly employed for the detection of circulating tumor cells (CTCs) and extracellular vesicles (EVs), which are valuable biomarkers for cancer diagnosis, prognosis, and monitoring of treatment response. These biosensors utilize various capture strategies, including specific antibodies or aptamers, to isolate and detect these rare cells or vesicles from biological samples. The integration of microfluidics with electrochemical detection allows for efficient enrichment and analysis, enabling early cancer detection and personalized therapeutic strategies. Advancements in signal amplification and multiplexing are enhancing the sensitivity and scope of these platforms [6].
The use of nanomaterials, such as nanoparticles, nanowires, and graphene, has significantly improved the performance of electrochemical biosensors. These materials offer high surface area, enhanced conductivity, and tunable surface chemistry, leading to improved sensitivity, selectivity, and stability. In biomedicine, nanomaterial-modified electrodes are crucial for detecting low-abundance biomarkers, accelerating reaction kinetics, and enabling multiplexed detection. Their integration facilitates the development of ultrasensitive and miniaturized diagnostic devices for various medical conditions [7].
Electrochemical biosensors play a vital role in point-of-care testing (POCT) by enabling rapid, on-site detection of various health indicators. The advantages of electrochemical POCT devices include their portability, ease of use, low cost, and ability to provide quantitative results quickly. Recent developments in microfluidics, materials science, and signal processing have led to the creation of sophisticated POCT devices for diagnosing infectious diseases, monitoring glucose levels, and detecting cardiac biomarkers. This accessibility is transforming healthcare delivery, especially in remote or resource-limited settings [8].
The development of electrochemical aptasensors has emerged as a powerful tool for biomedical analysis due to the unique properties of aptamers, such as their high specificity, stability, and ease of synthesis. These aptasensors offer a label-free or labeled detection mechanism for a wide range of biomolecules, including proteins, nucleic acids, and small molecules. Advances in aptamer selection and immobilization strategies, coupled with electrochemical signal transduction, are enabling the creation of highly sensitive and selective sensors for disease diagnosis, drug discovery, and molecular imaging [9].
Electrochemical impedimetric biosensors offer a label-free detection method that measures changes in electrical impedance at the electrode-analyte interface. This approach is particularly advantageous for detecting biomolecules that are difficult to label or when the intrinsic electrochemical properties of the analyte are not suitable for direct measurement. Recent progress in this area involves the use of advanced electrode materials and electrochemical models to improve sensitivity and specificity for applications such as detecting pathogens, monitoring cellular responses, and quantifying protein-protein interactions in biological systems [10].
Electrochemical bioanalysis provides a sensitive and specific platform for detecting biomolecules in biomedical applications, advancing point-of-care diagnostics, therapeutic drug monitoring, and disease biomarker identification. Innovations in nanomaterials and miniaturization enhance sensor performance for early disease detection and personalized medicine. Wearable electrochemical sensors enable continuous health monitoring through real-time analysis of biofluids. Electrochemical immunoassay platforms offer high specificity for detecting disease-specific proteins and antibodies. Electrochemical DNA biosensors are crucial for genetic diagnostics and detecting nucleic acid-based biomarkers. The detection of circulating tumor cells and extracellular vesicles using electrochemical methods aids in cancer diagnostics and treatment monitoring. Nanomaterial-modified electrodes are essential for ultrasensitive and miniaturized diagnostic devices. Electrochemical biosensors are vital for point-of-care testing, offering rapid, on-site detection. Electrochemical aptasensors provide a powerful tool for detecting various biomolecules with high specificity. Electrochemical impedimetric biosensors enable label-free detection of biomolecules by measuring impedance changes.
None
None
Journal of Bioanalysis & Biomedicine received 3099 citations as per Google Scholar report
